Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 2Lymphoid 1Head & Neck 1Breast 1

Conditions

Lymphoma 2Uterine Cervical Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Recurrence 1Lymphoma, T-Cell, Peripheral 1Lymphoma, Non-Hodgkin 1

Interventions

pembrolizumab 4Nivolumab 4Surveys and Questionnaires 3atezolizumab 2aflibercept 2Specimen Handling 2Methods 2Magnetic Resonance Spectroscopy 2Blood Specimen Collection 2zimberelimab 1ulixertinib 1trastuzumab biosimilar HLX02 1trametinib 1sapanisertib 1relatlimab 1pertuzumab 1palbociclib 1osimertinib 1omipalisib 1larotrectinib 1ipatasertib 1fludarabine 1erdafitinib 1entinostat 1durvalumab 1defactinib 1dabrafenib 1copanlisib 1ciforadenant 1cemiplimab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Uterine Cervical Neoplasms × ASTX-660 × Lymphoid × Clear all
NCT02503423 2026-03-20

Phase 1-2 Study of ASTX660 in Subjects With Advanced Solid Tumors and Lymphomas

Taiho Oncology, Inc.

Phase 1/2 Active not recruiting
253 enrolled
GynecologicHead & NeckLymphoid

Squamous Cell Carcinoma of Head and Neck, Uterine Cervical Neoplasms, Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡